Pharmacotherapy Original research| Volume 34, ISSUE 8, P1655-1666.e5, August 2012

Effect of Once-Daily Fluticasone Furoate/Vilanterol on 24-Hour Pulmonary Function in Patients With Chronic Obstructive Pulmonary Disease: A Randomized, Three-Way, Incomplete Block, Crossover Study



      Available inhaled corticosteroid/long-acting β2-agonist combinations for chronic obstructive pulmonary disease (COPD) require twice-daily administration. The combination of fluticasone furoate (FF) and vilanterol (VI) FF/VI is being developed in a novel dry powder inhaler for the treatment of COPD and asthma with the potential for once-daily dosing. Results from Phase II studies have shown clinically and statistically significant improvements over placebo in trough (24-hour postdose) forced expiratory volume in 1 second (FEV1) after once-daily dosing with FF or VI (VI concurrently with an inhaled corticosteroid) in asthma and VI in COPD.


      This Phase III, multicenter, randomized, double-blind, placebo-controlled study was designed based on guidance from drug regulators with the goal of evaluating the 24-hour spirometric effect of once-daily FF/VI in patients with COPD.


      Patients (aged ≥40 years) who completed a 2-week placebo run-in period were randomized to 1 of 18 three-course sequences of placebo and 2 of 3 dose combinations of FF/VI (50/25 μg, 100/25 μg, and 200/25 μg), dosed once daily in the morning. Each 28-day treatment period was separated by a 2-week, single-blind, placebo washout period. The primary end point was time-adjusted (weighted mean) 0 to 24-hour FEV1 (AUC) at the end of each 28-day treatment period (period days 28–29). Safety profile assessments included incidence of adverse events (AEs) (defined according to the Medical Dictionary for Regulatory Activities), 12-lead ECG outputs, vital signs (pulse rate, diastolic and systolic blood pressure) and clinical laboratory assessments (including fasting serum glucose and potassium) and 24-hour serum cortisol. The pharmacokinetics of FF and VI were assessed at the end of each 28-day treatment period with FF/VI.


      Eighty-seven patients were screened; 54 completed run-in and were randomized to double-blind treatment. The mean patient age was 57.9 years, and 46% were male. The majority of patients were current smokers (83%) and were receiving short-acting β2-agonists within the 3 months before screening (63%). All 3 strengths of once-daily FF/VI demonstrated significantly higher 0 to 24-hour (period days 28–29) change from period baseline weighted mean FEV1 than placebo: adjusted mean improvements from placebo in FEV1 for FF/VI were 220 to 236 mL (all, P < 0.001). Improvements versus placebo in change from period baseline serial FEV1 measures were observed at each time-point and with each strength of FF/VI over the 0 to 25-hour period (period days 28–29), indicating sustained bronchodilation. The overall incidence of on-treatment AEs was low (10%–12% with FF/VI; 4% with placebo); 2 serious AEs were reported during washout periods (1 AE after FF/VI 50/25 μg and 1 AE after placebo) but neither was considered treatment related. No serious AEs were reported during the treatment periods or during the follow-up period. No clinically or statistically significant differences from placebo were reported for serum glucose or potassium. No significant effects on vital signs, ECG, or 24-hour serial serum cortisol were reported. The extent of systemic exposure to FF and VI at steady state was low for all strengths of FF/VI.


      FF/VI inhaled once daily in the morning for 28 days produced significant improvements in pulmonary function with a prolonged (>24 hours') duration of action in this population of patients with COPD. The combination was well tolerated. identifier: NCT01072149.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Global Initiative for Chronic Obstructive Lung Disease (GOLD)
        2011 Guidelines on COPD diagnosis, prevention and management.
        (Accessed June 28, 2012)
        • Mahler D.A.
        • Wire P.
        • Horstman D.
        • et al.
        Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2002; 166: 1084-1091
        • Hanania N.
        • Feldman G.
        • Zachgo W.
        • et al.
        The efficacy and safety of the novel long-acting β2 agonist vilanterol in COPD patients: a randomized placebo-controlled trial.
        Chest. 2012 Jan 12; ([Epub ahead of print])
        • Calverley P.
        • Pauwels R.
        • Vestbo J.
        • et al.
        • TRial of Inhaled STeroids ANd long-acting beta2 agonists study group
        Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
        Lancet. 2003; 361: 449-456
        • Calverley P.M.
        • Boonsawat W.
        • Cseke Z.
        • et al.
        Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.
        Eur Respir J. 2003; 22: 912-919
        • Kardos P.
        • Wencker M.
        • Glaab T.
        Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
        Am J Resp Crit Care Med. 2007; 175: 144-149
        • Calverley P.M.
        • Anderson J.A.
        • Celli B.
        • et al.
        Efficacy of salmeterol and fluticasone propionate on mortality in chronic obstructive pulmonary disease: the TORCH survival trial.
        N Engl J Med. 2007; 356: 775-789
        • Tashkin D.P.
        • Rennard S.I.
        • Martin P.
        • et al.
        Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
        Drugs. 2008; 68: 1975-2000
        • Celli B.R.
        • Thomas N.E.
        • Anderson J.A.
        • et al.
        Effect of pharmacotherapy on rate of decline of lung function in COPD: results from the TORCH study.
        Am J Respir Crit Care Med. 2008; 178: 332-338
        • Saini S.D.
        • Schoenfeld P.
        • Kaulback K.
        • et al.
        Effect of medication dosing frequency on adherence in chronic diseases.
        Am J Manag Care. 2009; 15: e22-e33
        • Morrison V.
        • Sturton G.
        • Barrett V.
        • et al.
        Pharmacological characterisation of GW642444, a long-acting ß2-agonist (LABA) with rapid onset and long duration, on isolated large and small human airways.
        Am J Respir Crit Care Med. 2010; 181: A4453
        • Salter M.
        • Biggadike K.
        • Matthews J.L.
        • et al.
        Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease.
        Am J Physiol Lung Cell Mol Physiol. 2007; 293: L660-L667
        • Biggadike K.
        Fluticasone furoate/fluticasone propionate—different drugs with different properties.
        Clin Respir J. 2011; 5: 183-184
        • Celli B.R.
        • MacNee W.
        Standards of the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.
        Eur Respir J. 2004; 23: 932-946
        • Hankinson J.L.
        • Odencrantz J.R.
        • Fedan K.B.
        Spirometric reference values from a sample of the general US population.
        Am J Respir Crit Care Med. 1999; 159: 179-187
        • Mahler D.
        • Wells C.
        Evaluation of clinical methods for rating dyspnea.
        Chest. 1988; 93: 580-586
        • World Medical Association
        Declaration of Helsinki—ethical principles for medical research involving human subjects.
        (supports decl Hel) (Accessed June 28, 2012)
        • International Conference on Harmonisation (ICH)
        Guidance for Good Clinical Practice.
        (Accessed June 28, 2012)
        • Brown H.
        • Prescott R.
        Applied Models in Medicine: Statistics in Practice.
        John Wiley and Sons Ltd, United Kingdom2006
        • Donohue J.F.
        Minimal clinically important differences in COPD lung function.
        COPD. 2005; 2: 111-124
        • Lötvall J.
        • Bakke P.
        • Bjermer L.
        • et al.
        Efficacy and safety of four weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial.
        BMJ Open. 2012; 2: e000370
        • Lötvall J.
        • Bateman E.D.
        • Bleecker E.R.
        • et al.
        24h duration of the novel LABA vilanterol trifenatate in asthma patients treated with ICSs.
        Eur Respir J. 2012 Feb 23; ([Epub ahead of print])
        • Sterling R.
        • Lim J.
        • Frith L.
        • et al.
        Efficacy and optimal dosing interval of the long-acting beta2 agonist, vilanterol, in persistent asthma: a randomised trial.
        Resp Med. 2012; 106: 1110-1115
        • Bateman E.D.
        • Bleecker E.R.
        • Busse W.
        • et al.
        Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial.
        Resp Med. 2012; 106: 642-650
        • Bleecker E.R.
        • Bateman E.D.
        • Busse W.
        • et al.
        Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy.
        Eur Respir J. 2010; 36: 204s
        • Busse W.
        • Bleecker E.R.
        • Bateman E.D.
        • et al.
        Fluticasone furoate demonstrates efficacy in asthma patients symptomatic on medium doses of inhaled corticosteroid therapy: a randomised, placebo-controlled trial.
        Thorax. 2012; 67: 35-41
        • Gartlehner G.
        • Hansen R.A.
        • Carson S.S.
        • et al.
        Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis.
        Ann Fam Med. 2006; 4: 253-262
        • Pauwels R.A.
        • Lofdahl C.G.
        • Laitinen L.A.
        • et al.
        Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking.
        N Engl J Med. 1999; 340: 1948-1953
        • Burge P.S.
        • Calverley P.M.
        • Jones P.W.
        • et al.
        Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
        BMJ. 2000; 320: 1297-1303
        • Vestbo J.
        • Sorensen T.
        • Lange P.
        • et al.
        Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.
        Lancet. 1999; 353: 1819-1823
        • The Lung Health Study Research Group
        Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease: Lung Health Study II.
        N Engl J Med. 2000; 343: 1902-1909


        • Miller M.R.
        • Hankinson J.
        • Brusasco V.
        • et al.
        • ATS/ERS Task Force
        Standardisation of spirometry.
        Eur Respir J. 2005; 26: 319-338